Tag Archives: covid-19

Stopping the Bleeding of the Horseshoe Crab

Leave a reply

Every April in South Carolina, fishermen catch hundreds of horseshoe crabs as they crawl onto shore to mate. The crabs are transported to labs owned by Charles River, an American pharmaceutical company, in Charleston. There they are strapped to steel countertops and, still alive, drained of about a third of their blue-colored blood. Then they are returned to the ocean. This liquid is vital for America’s biomedical industry. A liter of it goes for as much as $15,000. Bleeding is not without harm to the crabs. Conservationists estimate that between 5% and 30% of them die on release…In 2016 the International Union for Conservation of Nature listed them as “vulnerable” to extinction… 

Parts of modern medicine have been unusually reliant on the horseshoe crab. Its blood is the only known natural source of limulus amebocyte lysate (LAL), an extract that detects endotoxin, a nasty and sometimes fatal bacterium. Drug firms use it to ensure the safety of medicines and implanted devices, including antibiotics, anti-cancer drugs, heart stents, insulin and vaccines. The immune cells in the crab’s blood clot around toxic bacteria, giving a visual signal of unwanted contamination. As pharmaceutical companies ramped up production of the covid-19 jab, demand for the blue liquid soared. In 2020 nearly 650,000 crabs were bled in America, 36% more than in 2018.

As crab numbers fall and demand for LAL rises, America’s biomedical industry will face a crunch. Yet a synthetic alternative to LAL is already available and used in China and Europe.

Excerpt from In America, crab blood remains vital for drug- and vaccine-making, Economist, Sept. 3, 2022

Begging for a Vaccine: the other COVID crisis

Leave a reply

On April 16, 2021  Adar Poonawalla, head of the world’s biggest vaccine-maker, the Serum Institute of India (SII), begged President Joe Biden, in a tweet, to ‘lift the embargo of raw material exports out of the us.’… because it would affect the manufacturing of vaccines: AstraZeneca’s, of which SII makes 100m doses a month, and Novavax’s, of which it expects to make 60m-70m doses a month.

That was shortly after the Biden administration announced, on February 5, 2021, plans to use the Defense Production Act (DPA)—a law dating from the 1950s that grants the president broad industrial-mobilization powers—to bolster US vaccine-making. This legislation…has helped American pharmaceutical companies to secure a variety of special materials and equipment, including plastic tubing, raw goods, filters and even paper, that are needed for vaccine production. But firms which export such products point out that the DPA  hinders their ability to sell them abroad. They must seek permission before exporting these goods. That requires time and paperwork. And if the government decides it needs the goods in question to remain in the country, the firms concerned may be barred from exporting them at all… 

To be used in vaccine manufacturing, products have to be approved by regulators. So finding substitutes quickly can be impossible. SII is not alone in its concern. On March 24, 2021  Micheal Martin, Ireland’s prime minister, warned that export bans (and not just from America) would harm global vaccine production. He noted that the Pfizer vaccine involves 280 components from 86 suppliers in 19 countries. Indeed, American export controls particularly harm European vaccine companies, which need special bags from America in which to make their products. At a vaccine supply-chain meeting in March, one such firm complained of 66-week delivery times for the supply of these bags.

Excerpts from A Vaxxing Problem: Covid 19 and the Defense Production Act, Economist, Apr. 24, 2021

Severe Damage to Beliefs Lasting a Lifetime: covid-19

Leave a reply

According to a new study  “Scarring Body and Mind: The Long-Term Belief-Scarring
Effects of COVID-19” the largest economic cost of the COVID-19 pandemic could arise from changes in behavior long after the immediate health crisis is resolved. A potential source of such a long-lived change is scarring of beliefs, a persistent change in the perceived probability of an extreme, negative shock in the future. Even if a vaccine cures everyone in a year, the COVID-19 crisis will leave its mark on the US economy for many years to come because of the mass revision of beliefs that lasts through a lifetime. Even before the COVID-19 pandemic, people were aware of the disruptive impacts that a pandemic could theoretically have on their lives and the economy. But the tangible, persistent and severe harms associated with an actual pandemic change beliefs about the probability of another similar shock in ways that abstract knowledge cannot.

Excerpts from Free Exchange: Razing Hopes, Economist, Aug. 29, 2020 [adapted]

Everyone for Themselves: COVID-19 Drug Reserved for U.S.

Leave a reply

On June 29, 2020 the US Department of Health and Human Services (HHS) announced an agreement to secure large supplies of the drug remdesivir for the United States from Gilead Sciences through September, allowing American hospitals to purchase the drug in amounts allocated by HHS and state health departments….HHS has secured more than 500,000 treatment courses of the drug for American hospitals through September. This represents 100% of Gilead’s projected production for July (94,200 treatment courses), 90% of production in August (174,900 treatment courses), and 90% of production in September (232,800 treatment courses), in addition to an allocation for clinical trials. A treatment course of remdesivir is, on average, 6.25 vials.

Hospitals will receive the product shipped by AmerisourceBergen and will pay no more than Gilead’s Wholesale Acquisition Price (WAC), which amounts to approximately $3,200 per treatment course.

Excerpts from Trump Administration Secures New Supplies of Remdesivir for the United States, June 29, 2020

Plastic Bags Back in Vogue: Blame COVID or Plastics Industry?

Leave a reply

Plastic bags may make a temporary comback in some places because of COVID-19.
In a setback, albeit temporary, for efforts to combat plastic waste, many state and local governments have suspended plastic bag bans and are prohibiting the use of reusable bags to stem the spread of COVID-19. The plastics industry is pushing for such measures, causing environmentalists to cry foul. San Francisco, which has been at the forefront of single-use plastics restrictions, issued an order “not permitting customers to bring their own bags, mugs, or other reusable items from home” as a measure “to prevent unnecessary contact.” Maine is delaying enforcement of its plastic bag ban to Jan. 15, 2021, after originally planning to roll it out on April 22—Earth Day….

The plastics industry has been advocating for such measures. In recent weeks, Bag The Ban, an initiative sponsored by the American Recyclable Plastic Bag Alliance, has endorsed editorials in newspapers such as the Boston Herald and the New Hampshire Union Leader advocating use of plastic bags to protect grocery workers from COVID-19.

Writing to the US Department of Health and Human Services, the Plastics Industry Association made a similar point. “Single-use plastic products are the most sanitary choice when it comes to many applications.” The association cited research on reusable bags, including a 2011 study from Loma Linda University and the University of Arizona that tested bags from shoppers selected randomly at the grocery store and found bacteria such as E. coli on 8% of them. It also pointed to a 2012 outbreak of norovirus in Oregon linked to use of a reusable food bag and cited a 2019 study from Portugal that found bacteria in bags.

Alexander H. Tullo, Plastic bag bans rolled back for COVID-19, Apr. 7, 2020

Can’t Treat Covid-19 with Flip-Flops

Leave a reply

The U.S. Covid-19 response remains a work in progress—fragmented, chaotic, and plagued by contradictory messaging from political leaders, [such as the flip-flops on the use of face masks, see Stop Buying Face Masks , Learn How to Make Your Own Face Mask]. …

 “We don’t have a national plan,” says epidemiologist Michael Osterholm of the University of Minnesota, Twin Cities. “We are going from press conference to press conference and crisis to crisis … trying to understand our response.”…Even if lockdowns succeed at halting the virus…. the United States needs to marshal massive resources to monitor for new outbreaks and quickly contain them…. Identifying cases and contacts and isolating them will require a huge increase in public health workers at the local level….The absence of nationwide coordination highlights the division of legal power between the federal and state governments…. Governors, not federal officials, typically hold police powers to shut businesses and enforce curfews. But many are reluctant to invoke those powers and suffer the political costs without clear direction from above….“The closest comparison here, in terms of national mobilization, is a war. And there is no way the United States would fight a war as 50 separate states.”

Excerpts from United States Strains to Act as Cases Set Record, Science Magazine, Apr. 3, 2020, at 6488.